Pharmaceutical Executive podkast

Pharmaceutical Executive Daily: FDA Approves Pimjetmi

0:00
2:14
Do tyłu o 15 sekund
Do przodu o 15 sekund
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

Więcej odcinków z kanału "Pharmaceutical Executive"